ArticleInternational urology and nephrology2025
Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer exhibits high incidence among males, yet the clinical utility of surgical intervention for non-metastatic disease remains controversial.
methodsWe extracted 290,749 cases from the SEER database (2010-2015) and categorized patients into a curative-directed surgery (CDS) group and a non-CDS group (surgery recommended but not performed). Propensity score matching (PSM) was applied to balance baseline characteristics. Survival analysis was conducted using Kaplan-Meier methods with stratified cumulative hazard curves, followed by multivariable Cox proportional hazards regression to estimate hazard ratios (HRs). Model selection was performed using the corrected Akaike Information Criterion (AICc).
resultsAfter propensity score matching (PSM), each group consisted of 8,330 patients. The cumulative risk curves indicated no significant survival benefit in the CDS group compared to the non-CDS group (p = 0.34). Stratified analysis revealed age-dependent risk escalation, particularly pronounced in patients over 74 years old. Surgery was found to reduce the risk in stage T2 patients but had no such effect on stage T1 patients. Increased PSA levels and Gleason scores significantly worsened prognosis (p < 0.0001). Multivariate Cox regression analysis demonstrated that Gleason score is a critical factor influencing mortality risk, with high-risk Gleason scores (8-10) conferring a 6.31-fold (95% CI 6.23-8.58) increase in risk compared to low-risk scores (≤ 6), consistent with the trend observed in the cumulative risk curves.
conclusionFor non-metastatic prostate cancer, surgical intervention may not confer a survival benefit, underscoring the need for cautious clinical decision-making. These findings warrant validation through prospective studies to elucidate the underlying mechanisms and refine treatment guidelines.
Indexed as
Identifiers
40205124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.